Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

24.040
-0.160-0.66%
Volume:2.09M
Turnover:50.25M
Market Cap:20.96B
PE:70.15
High:24.280
Open:24.000
Low:23.840
Close:24.200
52wk High:30.750
52wk Low:18.360
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.93
T/O Rate:0.24%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.343
ROE:46.90%
ROA:-0.81%
PB:2.20
PE(LYR):70.15
PS:4.48

Loading ...

Press Release: HUTCHMED Announces Appointment of Acting Chief Executive Officer

Dow Jones
·
Aug 25

Hutchmed Completes Patient Enrollment in Phase 3 Study of Lung Cancer Combination Treatment

MT Newswires Live
·
Aug 20

HUTCHMED (00013) Completes Patient Enrollment for SANOVO China Phase III Study Evaluating ORPATHYS® and TAGRISSO® Combination Therapy for First-Line Treatment of Specific Lung Cancer Patients

Stock News
·
Aug 20

HUTCHMED Completes Patient Enrollment of Sanovo Phase Iii Trial of Orpathys® and Tagrisso® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

THOMSON REUTERS
·
Aug 20

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

GlobeNewswire
·
Aug 20

Master Tec Group Malaysia 2nd-Quarter 2025 Earnings Summary Table

Dow Jones
·
Aug 11

HK Movers | HUTCHMED Collapses 14% After Rev. Slides; ZAI LAB Tumbles over 11% 2Q Rev. Growth Misses

Tiger Newspress
·
Aug 08

Stock Track | HUTCHMED Plummets 7.49% as FY25 Revenue Guidance Update Disappoints Investors

Stock Track
·
Aug 08

BRIEF-Hutchmed (China) Updates FY25 Guidance For Oncology/Immunology Consol Rev To $270M - $350M

Reuters
·
Aug 07

Hutchmed H1 Earnings Rise, Revenue Falls

MT Newswires Live
·
Aug 07

Earnings Flash (HCM) Hutchmed Posts H1 Earnings $2.61 Per ADS

MT Newswires Live
·
Aug 07

HUTCHMED (China) H1 EPS $2.65 Up From $0.15 YoY, Sales $277.677M Down From $305.681M YoY

Benzinga
·
Aug 07

HUTCHMED (China) - Updates FY25 Guidance for Oncology/Immunology CONSOL Revenue to $270 Mln - $350 Mln

THOMSON REUTERS
·
Aug 07

HUTCHMED Reports 2025 Interim Results

THOMSON REUTERS
·
Aug 07

Corrected-HUTCHMED (China) H1 Revenue USD 277.7 Million (Corrects Amount)

THOMSON REUTERS
·
Aug 07

HUTCHMED (China) Is Maintained at Buy by B of A Securities

Dow Jones
·
Jul 23

BOCOM International: Innovative Drug Sector's Recovery Prospects Remain Attractive; Focus on Commercial Insurance Drug Catalog Launch

Stock News
·
Jul 16

HUTCHMED (China) Ltd. Schedules Board Meeting to Approve and Announce 2025 Interim Results

Reuters
·
Jul 03

HUTCHMED to Announce 2025 Half-Year Financial Results

GlobeNewswire
·
Jul 03

Hutchmed New Drug Application for Lung Cancer Combination Treatment Approved in China

MT Newswires Live
·
Jun 30